Show simple item record

dc.contributor.authorLipowska-Bhalla, Grazyna
dc.contributor.authorFagnano, Ester
dc.contributor.authorIllidge, Timothy M
dc.contributor.authorCheadle, Eleanor J
dc.date.accessioned2016-04-22T15:07:14Zen
dc.date.available2016-04-22T15:07:14Zen
dc.date.issued2016-04-06en
dc.identifier.citationoving therapeutic activity of anImprti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. 2016:1-12 Leuk Lymphomaen
dc.identifier.issn1029-2403en
dc.identifier.pmid27050042en
dc.identifier.doi10.3109/10428194.2016.1157874en
dc.identifier.urihttp://hdl.handle.net/10541/606645en
dc.description.abstractNearly two decades ago rituximab heralded a new era in management of B cell malignancies significantly increasing response rates and survival. However, despite clear therapeutic advantage, significant numbers of patients become refractory to anti-CD20 mAb therapy, suggesting urgent improvements are required. It is now well recognized that the suppressive tumor microenvironment plays an important role in the outcome of anti-CD20 mAb therapy and that manipulation of this environment may improve the efficacy and produce long-term tumor control. The past few years have seen a surge of interest in immunomodulatory agents capable of overwriting immune suppressive networks into favorable clinical outcome. Currently, a number of such combinations with anti-CD20 mAb is under evaluation and some have produced encouraging outcomes in rituximab refractory disease. In this review, we give an outline of anti-CD20 mAbs and explore the combinations with immunomodulatory agents that enhance antitumor immunity through targeting stimulatory or inhibitory pathways and have proven potential to synergize with anti-CD20 mAb therapy. These agents, primarily mAbs, target CTLA-4, PD-1/PD-L1, and CD40.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Leukemia & lymphomaen
dc.titleImproving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.en
dc.typeArticleen
dc.contributor.departmentTargeted Therapy Group, Institute of Cancer Sciences, University of Manchester, Manchester Cancer Research Centre, Manchester Academic Health Sciences Centre , Manchesteren
dc.identifier.journalLeukemia & Lymphomaen
dc.description.collectionLymphoma Research Teamen
html.description.abstractNearly two decades ago rituximab heralded a new era in management of B cell malignancies significantly increasing response rates and survival. However, despite clear therapeutic advantage, significant numbers of patients become refractory to anti-CD20 mAb therapy, suggesting urgent improvements are required. It is now well recognized that the suppressive tumor microenvironment plays an important role in the outcome of anti-CD20 mAb therapy and that manipulation of this environment may improve the efficacy and produce long-term tumor control. The past few years have seen a surge of interest in immunomodulatory agents capable of overwriting immune suppressive networks into favorable clinical outcome. Currently, a number of such combinations with anti-CD20 mAb is under evaluation and some have produced encouraging outcomes in rituximab refractory disease. In this review, we give an outline of anti-CD20 mAbs and explore the combinations with immunomodulatory agents that enhance antitumor immunity through targeting stimulatory or inhibitory pathways and have proven potential to synergize with anti-CD20 mAb therapy. These agents, primarily mAbs, target CTLA-4, PD-1/PD-L1, and CD40.


This item appears in the following Collection(s)

Show simple item record